contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Curasight er en dansk biotekvirksomhed med fokus på at udvikle og forbedre opdagelsen og behandlingen af kræft på en mere skånsom og effektiv måde. På nuværende tidspunkt modtager patienter radioaktiv stråling i behandlingen mod kræft. Dette skader kræftcellerne, såvel som raske celler og væv i kroppen. Curasight teknologi er baseret på formålet om ikke at skade raske celler og væv. Virksomheden har to pipeline-produkter, der begge bruger radionuklid (nuklearmedicin) til at forbedre diagnosticering og behandling af forskellige kræfttyper; uTRACE bruger den såkaldte uPAR receptore som sidder på kræftceller, som en biomarkør til at diagnosticere kræften, samt dens udvikling. Selskabets andet product uTREAT, anvender uPAR som en receptor til at behandle kræften.

Baseret på stærke fase 2-data, der allerede er indsamlet i 2022, forventes Curasight at forberede fase 3 til uTRACE senere i 2022 og 2023 for følgende fire kræfttyper: prostata, hjerne, neuroendokrine og hoved- og halskræft.

Curasight

Copenhagen, Denmark, 27 November 2025 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report Q3 2025. The interim report is available as an attached...

<div class="abstract">Copenhagen, Denmark, 27 November 2025 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report Q3 2025. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.</div>Curasight's CEO Ulrich Krasilnikoff comments:"During the third quarter of 2025 and period after, Curasight continued to make significant clinical and strategic progress as we advance our mission to improve outcomes for patients with serious cancers through precision diagnostics and targeted radionuclide therapy. Our pipeline is moving forward on several key fronts. Most notably we are ready to enroll patients in the first clinical trial with our therapeutic platform uTREAT®, and remain on track to dose the first patient before the end of this year. We also continue to strengthen our intellectual property position and maintain momentum in our diagnostic platform uTRACE® phase II trial."Q3 (2025-07-01 - 2025-09-30)<ul>	<li>Gross loss amounted to kDKK -12,076 (kDKK -6,135) </li>	<li>Operating loss amounted to kDKK -13,545 (kDKK -8,099) </li>	<li>Loss before tax amounted to kDKK -14,262 (kDKK -8,523)</li>	<li>Loss for the period amounted to kDKK -19,204 (kDKK -10,737)</li>	<li>Total assets amounted to kDKK 33,202 (kDKK 25,778)</li>	<li>Equity ratio amounted to 52.6% (51.6%)</li>	<li>Earnings per share amounted to DKK -0.28 (DKK -0.35)</li></ul>Q1-Q3 (2025-01-01 - 2025-09-30)<ul>	<li>Gross loss amounted to kDKK -34,475 (kDKK -22,521)</li>	<li>Operating loss amounted to kDKK -38,765 (kDKK -28,443)</li>	<li>Loss before tax amounted to kDKK -41,420 (kDKK -30,002)</li>	<li>Loss for the period amounted to kDKK -24,408 (kDKK -18,729)</li>	<li>Total assets amounted to kDKK 33,202 (kDKK 25,778)</li>	<li>Equity ratio amounted to 52.6% (51.6%)</li>	<li>Earnings per share amounted to DKK -0.81 (DKK -1.25)</li></ul>Numbers in parenthesis are the numbers from the same period in 2024.<div></div>